Malignant glioma remains incurable despite tremendous advancement in basic research
and clinical practice. The identification of the cell (s) of origin should provide deep insights …

Cancer encompasses a complex, heterogeneous and dynamic group of diseases that arise
from perturbations to multiple biological networks within the body. A systems biology-based …

Background Surgical resection is a universal component of glioma therapy. Little is known
about the postoperative microenvironment due to limited preclinical models. Thus, we …

Purpose: Immune checkpoint inhibitors designed to revert tumor-induced
immunosuppression have emerged as potent anticancer therapies. Tryptophan metabolism …

Glioblastoma (GBM) is a highly aggressive and heterogeneous form of brain cancer.
Genotypic and phenotypic heterogeneity drives drug resistance and tumor recurrence …

As the list of putative driver mutations in glioma grows, we are just beginning to elucidate the
effects of dysregulated developmental signaling pathways on the transformation of neural …

Although our knowledge of the biology of brain tumors has increased tremendously over the
past decade, progress in treatment of these deadly diseases remains modest. Developing in …

Glioblastoma multiforme (GBM) is a malignant brain tumor that evades therapy regimens.
Since cellular dormancy is one strategy for surviving, and since chemokines determine the …

Rationale: The large-scale genomic analysis classifies glioblastoma (GBM) into three major
subtypes, including classical (CL), proneural (PN), and mesenchymal (MES) subtypes. Each …

Brain tumors are highly heterogeneous and have been classified by the World Health
Organization in various histological and molecular subtypes. Gliomas have been classified …